国际妇产科学杂志 ›› 2026, Vol. 53 ›› Issue (3): 322-328.doi: 10.12280/gjfckx.20251462

• 妇科肿瘤研究:病例报告 • 上一篇    下一篇

复发性宫颈癌伴膀胱-小肠瘘一例

刘尔愉, 任青于, 高翔()   

  1. 214026 江苏省无锡市, 江南大学附属医院肿瘤内科
  • 收稿日期:2025-12-22 出版日期:2026-06-15 发布日期:2026-07-06
  • 通讯作者: 高翔 E-mail:9862016084@jiangnan.edu.cn

A Case of Recurrent Cervical Cancer with Vesicoenteric Fistula

LIU Er-yu, REN Qing-yu, GAO Xiang()   

  1. Department of Medical Oncology, Affiliated Hospital of Jiangnan University, Wuxi 214026, Jiangsu Province, China
  • Received:2025-12-22 Published:2026-06-15 Online:2026-07-06
  • Contact: GAO Xiang E-mail:9862016084@jiangnan.edu.cn

摘要:

宫颈癌复发并自发形成膀胱-小肠瘘极为罕见,临床表现隐匿,易与放射性或炎性瘘管混淆。报告1例52岁女性,宫颈癌根治术后1年余因无痛性全程肉眼血尿就诊。影像学提示右侧盆壁肿块侵犯膀胱及回肠,并伴腹膜后、纵隔及左锁骨上淋巴结多发转移,PET/CT提示膀胱内积气,结合CT与MRI检查,临床高度怀疑膀胱-小肠瘘。患者入院后先后接受双侧髂内动脉栓塞止血及腹腔镜探查,术中证实距屈氏韧带130 cm处回肠与膀胱后壁形成直径5 cm瘘管。遂一期完成小肠部分切除+膀胱修补+乙状结肠造口+经皮肾盂造口。术后病理诊断为转移性低分化鳞癌,免疫组织化学检查提示程序性死亡受体配体1(programmed death-ligand 1,PD-L1)综合阳性评分(combined positive score,CPS)5分、表皮生长因子受体(epidermal growth factor receptor,EGFR)(3+)。术后予斯鲁利单抗联合白蛋白紫杉醇+卡铂方案治疗,评估疗效为病灶较前缩小,病情稳定(stable disease,SD)。本病例提示临床上当晚期宫颈癌出现难以解释的血尿或粪尿时,应警惕肿瘤性复杂瘘的可能;早期外科干预结合个体化免疫联合化疗可迅速缓解症状并控制病情,为类似危重病例的综合管理提供参考。

关键词: 宫颈肿瘤, 癌, 膀胱-小肠瘘, 复发, 免疫疗法, 斯鲁利单抗

Abstract:

Recurrent cervical cancer with spontaneous vesicoenteric fistula formation is extremely rare. Its clinical presentation is insidious and easily confused with radiation- or inflammation-induced fistulas. We report a 52-year-old female who presented with painless gross hematuria more than one year after radical hysterectomy for cervical cancer. Imaging revealed a right pelvic wall mass invading the bladder and ileum, along with multiple metastases in the retroperitoneal, mediastinal, and left supraclavicular lymph nodes. PET/CT showed air within the bladder. Combined with CT and MRI findings, a vesicoenteric fistula was strongly suspected. After admission, the patient underwent bilateral internal iliac artery embolization for hemostasis followed by laparoscopic exploration, which confirmed a 5 cm-diameter fistula between the ileum (130 cm distal to the ligament of Treitz) and the posterior bladder wall. One-stage surgery comprising partial small-bowel resection, bladder repair, sigmoid colostomy, and percutaneous nephrostomy was performed. Postoperative pathology confirmed metastatic poorly differentiated squamous cell carcinoma. Immunohistochemistry showed a programmed death-ligand 1 (PD-L1) combined positive score (CPS) of 5 and epidermal growth factor receptor (EGFR) (3+). After surgery, the patient received Serplulimab combined with albumin-bound Paclitaxel plus Carboplatin, and imaging evaluation indicated tumor shrinkage with stable disease (SD). This case highlights that unexplained hematuria or fecaluria in advanced cervical cancer should raise suspicion of a neoplastic complex fistula. Early surgical intervention combined with individualized immunotherapy combined with chemotherapy can rapidly relieve symptoms and control disease, providing a reference for the comprehensive management of similar critical cases.

Key words: Uterine cervical neoplasms, Carcinoma, Vesicoenteric fistula, Recurrence, Immunotherapy, Serplulimab